Protagonist (PTGX) Q2 Revenue Falls 26%

Protagonist Therapeutics (NASDAQ:PTGX), a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025. The most significant news from the release was the company’s continued advancement of its late-stage clinical pipeline, even as GAAP revenue fell short of consensus estimates. GAAP earnings per share showed a narrower loss of $0.55, outperforming the anticipated loss of $0.58. GAAP revenue was $5.5 million, falling well below the estimate of $7.51 million. The period underscored important regulatory and clinical progress, but also reinforced ongoing reliance on milestone-related payments and a lack of recurring revenues. Source: Analyst estimates for the quarter provided by FactSet. Protagonist Therapeutics develops peptide-based drugs targeting hematological (blood) and inflammatory diseases. Its main programs focus on polycythemia vera (a rare blood disorder) and plaque psoriasis. The business relies heavily on clinical milestones and strategic partnerships to fund operations as it moves therapies through late-stage development.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool